JP2007153894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007153894A5 JP2007153894A5 JP2006327355A JP2006327355A JP2007153894A5 JP 2007153894 A5 JP2007153894 A5 JP 2007153894A5 JP 2006327355 A JP2006327355 A JP 2006327355A JP 2006327355 A JP2006327355 A JP 2006327355A JP 2007153894 A5 JP2007153894 A5 JP 2007153894A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- kinase
- mediated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002159 abnormal effect Effects 0.000 claims description 10
- 230000010261 cell growth Effects 0.000 claims description 9
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 8
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 8
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- -1 2,6-Dichloro-3-fluoro-phenyl Chemical group 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- AKQZEFRALAUBFS-UHFFFAOYSA-N ilamine Natural products COC(C)C(O)(C(=O)OCC1=CCN2CCCC12)C(C)(C)O AKQZEFRALAUBFS-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 208000014618 spinal cord cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74276605P | 2005-12-05 | 2005-12-05 | |
| US86463706P | 2006-11-07 | 2006-11-07 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007153894A JP2007153894A (ja) | 2007-06-21 |
| JP2007153894A5 true JP2007153894A5 (enExample) | 2010-05-27 |
| JP4619346B2 JP4619346B2 (ja) | 2011-01-26 |
Family
ID=38123250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006327355A Active JP4619346B2 (ja) | 2005-12-05 | 2006-12-04 | 異常細胞成長の処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7825137B2 (enExample) |
| EP (1) | EP1959955B1 (enExample) |
| JP (1) | JP4619346B2 (enExample) |
| KR (1) | KR101026676B1 (enExample) |
| AR (1) | AR056832A1 (enExample) |
| AT (1) | ATE488237T1 (enExample) |
| AU (1) | AU2006323027B2 (enExample) |
| BR (1) | BRPI0619424B1 (enExample) |
| CA (1) | CA2632286C (enExample) |
| CY (1) | CY1110931T1 (enExample) |
| DE (1) | DE602006018354D1 (enExample) |
| DK (1) | DK1959955T3 (enExample) |
| IL (1) | IL191471A (enExample) |
| NZ (1) | NZ568654A (enExample) |
| PL (1) | PL1959955T3 (enExample) |
| PT (1) | PT1959955E (enExample) |
| RU (1) | RU2384331C2 (enExample) |
| SI (1) | SI1959955T1 (enExample) |
| TW (1) | TWI321050B (enExample) |
| WO (1) | WO2007066187A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101023064B (zh) | 2004-08-26 | 2011-02-16 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
| DK1889836T3 (da) * | 2005-08-24 | 2013-08-19 | Eisai R&D Man Co Ltd | Hidtil ukendt pyridinderivat og pyrimidinderivat |
| EP1963302B1 (en) * | 2005-12-05 | 2013-02-27 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| PL2450437T3 (pl) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc | Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych |
| CA2661333C (en) * | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| JP2009132660A (ja) * | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| JPWO2009104520A1 (ja) * | 2008-02-18 | 2011-06-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の製造方法（２） |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
| WO2010064300A1 (ja) * | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| JP5675850B2 (ja) | 2010-02-05 | 2015-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヘタリール−［１，８］ナフチリジン誘導体 |
| US8378104B2 (en) * | 2010-02-11 | 2013-02-19 | OSI Pharmaceuticals, LLC | 7-aminofuropyridine derivatives |
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| KR20130131293A (ko) | 2010-07-05 | 2013-12-03 | 메르크 파텐트 게엠베하 | 키나아제 - 유도된 질환의 치료에 유용한 바이피리딜 유도체 |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| WO2012119006A2 (en) * | 2011-03-03 | 2012-09-07 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| US9051318B2 (en) | 2011-03-09 | 2015-06-09 | Merck Patent Gmbh | Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith |
| WO2013041038A1 (en) * | 2011-09-21 | 2013-03-28 | Teligene Ltd. | Pyridine compounds as inhibitors of kinase |
| CA2863515C (en) | 2012-01-31 | 2018-02-27 | Daiichi Sankyo Company, Limited | Pyridone derivatives |
| KR101692600B1 (ko) | 2012-03-06 | 2017-01-03 | 화이자 인코포레이티드 | 증식성 질환 치료용 거대환형 유도체 |
| WO2013148537A1 (en) * | 2012-03-29 | 2013-10-03 | Ning Xi | Substituted spirobicyclic compounds and methods of use |
| US20150056193A1 (en) | 2012-04-18 | 2015-02-26 | Cell Signaling Technology, Inc. | Egfr and ros1 kinase in cancer |
| CN103509008A (zh) * | 2012-06-22 | 2014-01-15 | 康瑟特制药公司 | 吡唑取代的氨基-杂芳基化合物的衍生物 |
| WO2014020467A2 (en) | 2012-07-30 | 2014-02-06 | Fresenius Kabi Oncology Ltd | Process for the preparation of pyrazole substituted aminoheteroaryl compounds |
| WO2014046730A1 (en) | 2012-09-24 | 2014-03-27 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker |
| CA2890006C (en) * | 2012-11-06 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EA201201654A1 (ru) * | 2012-12-28 | 2014-06-30 | Ооо "Эн.Си.Фарм" | Противоопухолевое средство (варианты) |
| WO2014115169A2 (en) * | 2013-01-24 | 2014-07-31 | Hetero Research Foundation | Crizotinib solid dispersion |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
| WO2014140159A1 (en) * | 2013-03-13 | 2014-09-18 | Ratiopharm Gmbh | Dosage form comprising crizotinib |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| JP6291179B2 (ja) * | 2013-07-26 | 2018-03-14 | 関東化學株式会社 | 光学活性２級アルコールの製造方法 |
| US20160214961A1 (en) * | 2013-09-10 | 2016-07-28 | Shilpa Medicare Limited | Novel salts of crizotinib and their preparation |
| RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| EP3066118B1 (en) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| JP2017530950A (ja) | 2014-08-25 | 2017-10-19 | ファイザー・インコーポレイテッド | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
| EP4089076A1 (en) | 2014-08-28 | 2022-11-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| KR102763349B1 (ko) | 2015-02-25 | 2025-02-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| US12066428B2 (en) * | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| CN109890387B (zh) | 2016-05-20 | 2022-06-14 | 拜尔哈文制药股份有限公司 | 谷氨酸调节剂与免疫疗法用以治疗癌症的用途 |
| GB201616116D0 (en) * | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| KR102539920B1 (ko) | 2017-02-08 | 2023-06-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양-치료용 약제학적 조성물 |
| SG11201910100PA (en) | 2017-05-16 | 2019-11-28 | Eisai R&D Man Co Ltd | Treatment of hepatocellular carcinoma |
| CN108047231B (zh) * | 2018-01-02 | 2020-02-11 | 江苏医药职业学院 | [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用 |
| IT201800003875A1 (it) * | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| EP4007585A4 (en) | 2019-08-02 | 2023-11-08 | OneHealthCompany, Inc. | TREATMENT OF CANINE CANCERS |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
| GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| JPH07109260A (ja) | 1993-10-12 | 1995-04-25 | Fuji Photo Film Co Ltd | ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法 |
| ES2161290T3 (es) * | 1995-03-30 | 2001-12-01 | Pfizer | Derivados de quinazolina. |
| SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| SE9801526D0 (sv) | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| MXPA01010292A (es) * | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
| JP2003523942A (ja) | 1999-06-30 | 2003-08-12 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害剤化合物 |
| BR0108363A (pt) | 2000-02-16 | 2004-02-10 | Neurogen Corp | Composto, métodos para modular função de receptor de crf e acoplado a proteìna g, para tratar um distúrbio ou doença do snc, para localizar receptores de crf em amostras de seção de tecidos, para inibir a ligação de crf a um receptor de crf¹ e para alterar a atividade de transdução de sinal de um receptor de crf¹ e composição farmacêutica |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| MXPA05009063A (es) * | 2003-02-26 | 2005-12-12 | Sugen Inc | Compuestos de aminoheteroarilo como inhibidores de proteina cinasa. |
| WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| AU2004319815A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| CN101023064B (zh) | 2004-08-26 | 2011-02-16 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
| ES2355923T3 (es) * | 2004-08-26 | 2011-04-01 | Pfizer, Inc. | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa. |
| WO2006021886A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| EP1963302B1 (en) * | 2005-12-05 | 2013-02-27 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
-
2006
- 2006-11-23 EP EP06820997A patent/EP1959955B1/en active Active
- 2006-11-23 PL PL06820997T patent/PL1959955T3/pl unknown
- 2006-11-23 PT PT06820997T patent/PT1959955E/pt unknown
- 2006-11-23 NZ NZ568654A patent/NZ568654A/en unknown
- 2006-11-23 AU AU2006323027A patent/AU2006323027B2/en active Active
- 2006-11-23 AT AT06820997T patent/ATE488237T1/de active
- 2006-11-23 WO PCT/IB2006/003397 patent/WO2007066187A2/en not_active Ceased
- 2006-11-23 DE DE602006018354T patent/DE602006018354D1/de active Active
- 2006-11-23 RU RU2008122471/14A patent/RU2384331C2/ru active
- 2006-11-23 US US12/095,114 patent/US7825137B2/en active Active
- 2006-11-23 KR KR20087016376A patent/KR101026676B1/ko active Active
- 2006-11-23 BR BRPI0619424-9A patent/BRPI0619424B1/pt active IP Right Grant
- 2006-11-23 CA CA2632286A patent/CA2632286C/en active Active
- 2006-11-23 SI SI200630864T patent/SI1959955T1/sl unknown
- 2006-11-23 DK DK06820997.2T patent/DK1959955T3/da active
- 2006-12-04 JP JP2006327355A patent/JP4619346B2/ja active Active
- 2006-12-04 TW TW095145034A patent/TWI321050B/zh active
- 2006-12-05 AR ARP060105369A patent/AR056832A1/es not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191471A patent/IL191471A/en active IP Right Grant
-
2010
- 2010-11-24 CY CY20101101055T patent/CY1110931T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007153894A5 (enExample) | ||
| CA2632286A1 (en) | Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer | |
| RU2014102935A (ru) | Кризотиниб для применения в лечении рака | |
| RU2010121647A (ru) | Полиморфы ингибитора c-met/hgfr | |
| Sonpavde et al. | Pazopanib: a novel multitargeted tyrosine kinase inhibitor | |
| RU2346702C2 (ru) | Применение антител к ctla-4 | |
| Stenman et al. | Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers | |
| Siziopikou et al. | The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies | |
| Carneiro et al. | FGFR3–TACC3: a novel gene fusion in cervical cancer | |
| JP2020508302A5 (enExample) | ||
| JPWO2019150305A5 (enExample) | ||
| JP2020105190A5 (enExample) | ||
| JP2023168298A5 (enExample) | ||
| Nemeth et al. | Oesophageal GIST—A rare breed case report and review of the literature | |
| Pogorzelska et al. | Novel 2-(2-alkylthiobenzenesulfonyl)-3-(phenylprop-2-ynylideneamino) guanidine derivatives as potent anticancer agents–Synthesis, molecular structure, QSAR studies and metabolic stability | |
| Hamad et al. | Neoadjuvant treatment with trastuzumab and FOLFOX induces a complete pathologic response in a metastatic ERBB2 (HER2)-amplified duodenal cancer | |
| Cao et al. | Analysis of the clinicopathological features and prognostic factors in 734 cases of Chinese Hui and Han patients with adenocarcinoma of the esophagogastric junction | |
| Masuda et al. | Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus | |
| George | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor | |
| Kumar et al. | Curative resection for adenocarcinoma of the gastro-esophageal junction following neo-adjuvant chemotherapy—thoraco-abdominal vs. trans-abdominal approach | |
| von Mehren | Recent advances in the management of gastrointestinal stromal tumors | |
| Patti et al. | Prognostic factors in esophageal cancer | |
| JPWO2022170974A5 (enExample) | ||
| Yu et al. | The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells | |
| Spanos | Digestive system malignancies |